alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Oncogenic Mutations'],"[{'ncitCode': 'C121854', 'drugName': 'Bemcentinib'}, {'ncitCode': 'C106432', 'drugName': 'Pembrolizumab'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],[],"[{'link': 'https://jitc.bmj.com/content/9/Suppl_2/A632.altmetrics', 'abstract': 'Li et al. Abstract # 602, JITC 2021.'}]","Bemcentinib is an inhibitor of the AXL receptor tyrosine kinase, and pembrolizumab is an anti-PD-1 antibody. In a phase II trial of bemcentinib + pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC), three evaluable patients with STK11 mutations demonstrated objective clinical response/clinical benefit. Additionally, preclinical data shows that AXL inhibition increases the efficacy of checkpoint blockade in STK11-deficient tumor models (Abstract: Li et al. Abstract # 602, JITC 2021. https://jitc.bmj.com/content/9/Suppl_2/A632.altmetrics)."
